{"id":"NCT01885000","sponsor":"Galderma R&D","briefTitle":"Patient-Reported Outcome Of Facial Erythema (PROOF)","officialTitle":"Patient-Reported Outcomes of Brimonidine Tartrate 0.5% Gel for Treatment of Severe Facial Erythema of Rosacea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-07-01","primaryCompletion":"2013-11-14","completion":"2013-11-14","firstPosted":"2013-06-24","resultsPosted":"2017-01-13","lastUpdate":"2021-08-25"},"enrollment":92,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rosacea","Erythema"],"interventions":[{"type":"DRUG","name":"Brimonidine tartrate was applied cutaneously once daily for 8 days.","otherNames":[]},{"type":"DRUG","name":"Brimonidine tartrate vehicle was applied cutaneously once daily for 8 days.","otherNames":[]}],"arms":[{"label":"Brimonidine tartrate 0.5% gel","type":"EXPERIMENTAL"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to evaluate the patient-reported outcomes (feedbacks of patients)of a new drug for the treatment of erythema of rosacea (central facial redness). The feedback of patients receiving the active drug will be compared to the feedback of patients receiving the placebo.","primaryOutcome":{"measure":"Percentage of Participants Who Are Very Satisfied/Satisfied/Somewhat Satisfied With the Overall Study Treatment","timeFrame":"Day 8","effectByArm":[{"arm":"Brimonidine Tartrate 0.5% Gel","deltaMin":69.6,"sd":null},{"arm":"Vehicle","deltaMin":40.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"= 0.0065"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":14,"countries":["Germany","Sweden","United Kingdom"]},"refs":{"pmids":["26416154"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":48},"commonTop":["Erythema","Skin tightness","Headache","Rosacea","Skin warm"]}}